Chronic viral hepatitis B
Conditions
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age 18 ~ 65 years old, male and female (including 18 and 65 years old); (2) HBsAg positive for 6 months or more; (3) The maximum quantitative titer of HBsAg was <5000IU/mL; (4) HBeAg negative chronic HBV infection; (5) Patients with long-acting interferon recommended in accordance with the Chronic Hepatitis B Prevention and Treatment Guidelines (2022 edition); (6) Willing and suitable to receive any of the following treatment options: Regimen 1: Long-acting interferon (Piagabin) monotherapy group (135ug or 180ug dose); Scheme 2: NAs drug group alone; Scheme 3: NAs combined with Pygabine initial treatment group; Plan 4: NAs combined with pergolbine sequential treatment group (NAs medication for at least six months); (7) Within 24 hours before the first medication, urine or serum pregnancy test is negative (only for women of childbearing age), and consent to the study; (8) Willing to take effective contraceptive measures during pregnancy or pregnancy; Voluntary entry, able to understand and sign informed consent;
Exclusion criteria
Exclusion criteria: (1) Short-term pregnancy plans, a history of mental illness (such as schizophrenia or severe depression), uncontrolled epilepsy, decompensated cirrhosis, uncontrolled autoimmune diseases, and underlying diseases such as severe infections, retinal diseases, heart failure, and chronic obstructive pulmonary disease. (2) combined with hepatitis A, C, D, E and/or HIV infection, or with other causes of chronic liver disease, such as alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease; (3) malignant tumors, or any history of organ transplantation and existing functional grafts (other than corneal or hair transplants); (4) persons who are allergic to pygabine, or who meet any contraindication in the instruction manual of the experimental drug; (5) Subjects deemed unsuitable for this study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg clearance;Serum conversion rate of HBsAg; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of cirrhosis;Incidence of liver cancer; | — |
Countries
China
Contacts
Public ContactLu Xiaobo
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed